CG
NGM

Cutler Group’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Cutler Group’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$4K Hold
3,100
– – ﹤0.01% 1677
2023
Q4 		$2K Hold
3,100
– – ﹤0.01% 3239
2023
Q3 		$3K Hold
3,100
– – ﹤0.01% 3198
2023
Q2 		$8K Hold
3,100
– – ﹤0.01% 2413
2023
Q1 		$12K Buy
3,100
+1,000
+48% +$4.62K ﹤0.01% 2246
2022
Q4 		$10K Buy
2,100
+700
+50% +$4.39K ﹤0.01% 2734
2022
Q3 		$18K Buy
1,400
+1,300
+1,300% +$19.7K ﹤0.01% 2706
2022
Q2 		$1K Buy
+100
New +$1.39K ﹤0.01% 4809
2021
Q4 		– Sell
-1,800
Closed -$34.5K – 6332
2021
Q3 		$37K Buy
1,800
+800
+80% +$17.6K ﹤0.01% 2787
2021
Q2 		$19K Sell
1,000
-1,100
-52% -$25.7K ﹤0.01% 3360
2021
Q1 		$61K Buy
2,100
+100
+5% +$2.8K ﹤0.01% 2203
2020
Q4 		$60K Buy
2,000
+1,600
+400% +$35K ﹤0.01% 1871
2020
Q3 		$6K Hold
400
– – ﹤0.01% 3421
2020
Q2 		$7K Buy
+400
New +$7.64K ﹤0.01% 3138

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cutler Group's NGM Position: Q1 2024 in Review

Cutler Group held its NGM Biopharmaceuticals, Inc. Common Stock (NGM) position steady in Q1 2024 at 3,100 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #1677.

Cutler Group first reported a position in NGM in Q2 2020 and has held it in 14 quarters since. The position peaked at $61K in Q1 2021. 75 funds tracked by Wall St. Rank hold NGM as of Q1 2024.

  • Cutler Group held 3,100 shares of NGM Biopharmaceuticals, Inc. Common Stock worth $4K as of Q1 2024.
  • Cutler Group left its NGM Biopharmaceuticals, Inc. Common Stock share count unchanged in Q1 2024.
  • NGM Biopharmaceuticals, Inc. Common Stock made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1677 holding.
  • Cutler Group first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2020 and has held it in 14 quarters since.
  • Cutler Group's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $61K in Q1 2021.
  • 75 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.